As a mage, I just want to pursue the truth

Chapter 157 Cooperation
The intrigues among the countries on Blue Star made Zheng Li realize that it was impossible for them to work together as a whole.

Even the cooperation between China and Russia has its reservations.

Originally, Zheng Li deliberately left a shortcut in the magic forum, which was for everyone to cooperate in purchasing technical information and then share it.

However, no one expected that even in the face of such a great temptation, the countries of Blue Star would be unable to reach cooperation.

If cooperation doesn't work, then the only option is competition.

Zheng Li realized that only by appropriately increasing the intensity of competition and limiting the scope of competition to the field of scientific research can the potential of Blue Star civilization be better stimulated.

Cooperation is a bit illusory for the Blue Star civilization where war is an eternal theme.

This may be the nature of intelligent life. Mages also fought endlessly in ancient and medieval times.

Li Wanqing said excitedly: "As long as you agree, I can definitely convince them. Speaking of biological storage servers, we can put all 1000PB of data on one storage server."

"The subsequent data processing speed can also be greatly increased, which is of great benefit to our processing of brain nerve signals."

The development of brain-computer-connected mobile phones for the mainstream languages ​​of Blue Star has been completed.

As for brain-computer VR, the research and development has been mainly completed in the Chinese and English language departments. The research and development of other languages ​​will be started according to the size of their market.

Zheng Li asked, "What are the test data of the brain-computer prosthesis in Jiangcheng?"

Li Wanqing: "The test data is very good. So far, none of the testers have experienced any accidents due to errors in the recognition of brain nerve signals."

"But the clinical trial of the prosthetic limbs in the English Department has been transferred from America to South Africa, and America has not approved our clinical trial application."

"The Chinese Department's brain-computer interface prosthetic limb is ready for production."

Ke Chuang Bio's brain-computer connection technology is non-invasive, so the approval process for the medical device to be marketed will be faster.

Zheng Lixiang imagined that a lot of manpower was invested in the research and development of innovative drugs at Kechuang Bio's R&D centers in Jiangcheng and Suzhou.

He asked: "What is the progress of the research and development of innovative drugs? Has any of them started clinical trials?"

It is true that the research and development of innovative drugs is difficult, but Ke Chuang Biotechnology has already started research and development in this field since its establishment in 19.

It’s just that Zheng Li himself has made relatively little contribution in this regard. According to the normal timeline, the research and development of innovative drugs will take ten years to produce certain results.

It takes about 3 to 6 years from early research to determining the chemical composition of a new drug, and 1 to 2 years for preclinical research.

After this long process, there is also clinical research and drug approval.

Domestic pharmaceutical companies generally start with generic drugs. It is extremely rare for a company like Kechuang Bio to start directly with innovative drugs.

He is a typical example of someone who is not short of money.

Li Wanqing replied: "We are still in the process of compound screening, and there are not many changes."

As the director of the R&D center in Lion City, Li Wanqing returned to Suzhou to attend the annual meeting of Ke Chuang Biotechnology and met some researchers from other R&D centers.

Whether from internal company forums or private circles of friends and chats among researchers, Ke Chuang Bio has not made much progress in the research and development of innovative drugs.

Among the major sectors of scientific and technological innovation and biology, brain-computer connection and endorphin fields are the main sources of profit.

In the area of ​​innovative drugs, only input is seen but no output is. The senior executives are all insiders in the biopharmaceutical field and know that this is normal.

However, the relevant person in charge will be anxious. With such a huge investment but no output, his voice and status within the company will inevitably be low.

If there is any breakthrough in research and development, it will definitely be widely publicized in order to increase its influence or gain more attention and support.

Li Wanqing hasn't heard anything so far. It seems like his colleagues in the entire innovative drug line have entered silent mode. He knows that there has obviously been no breakthrough.

This part will definitely be included in the weekly work summary for Zheng Li, but since there has been no progress on innovative drugs, it only takes up one sentence at most in the work report.

Zheng Li doesn't know much about the real situation of innovative drugs.

After listening to Li Wanqing's answer, he said: "Innovative drugs do require relatively large investments and are long-term investments."

"When I was working on endorphins, they were not considered innovative drugs, but generic drugs."

Li Wanqing flattered: "Endorphins were discovered by scientists in the last century, but no one has figured out how to make them, let alone how to mass-produce them."

“Your research results are no less difficult than any innovative drug.”

After endorphin was launched on the market, the drug's revenue and profits were no less than those of any multinational pharmaceutical giant's flagship products.

It can be said to be the foundation of scientific and technological innovation.

Even if billions of dollars are invested in innovative drugs, it is not necessarily possible to develop the next blockbuster product with similar effects. Take Pfizer as an example. Before sildenafil came out, it had a big gap with Merck in terms of both revenue and profit.

After the launch of sildenafil, Pfizer quickly surpassed Merck with just this one drug. Of course, Merck has made a comeback in the past two years.

But sildenafil took Pfizer straight to the next level.

Of course, Sinovation Biotech is different from Pfizer. Since the launch of the brain-computer interface mobile phone, the outside world has viewed Sinovation Biotech more as a diversified enterprise, not just limited to the biopharmaceutical field.

Zheng sorted out his thoughts. His hope for Ke Chuang Bio is to expand the scale, improve research and development capabilities, and be able to implement his research and development ideas when necessary.

Currently, Ke Chuang Bio is still in the development stage. After it stabilizes, Zheng Li plans to inspect the internal researchers and retain those with high ability limits.

After Huawei's biological storage server became popular, the outside world was discussing it, and the discussion in the industry was even more heated.

Especially Sugon, Inspur, Tsinghua Unigroup, and Yangtze Memory Technologies, all of which are industry companies, Huawei suddenly made false claims.

Why didn't I hear any news before?

Yangtze Memory Technologies is better off, after all, its vice president suddenly went to work for a central enterprise called Deep Blue Memory Technologies.

They have guessed what big news will happen in the domestic storage industry.

But they didn't expect that this movement was a bit beyond their imagination. Before biological storage, they had never heard of any domestic R&D team with mature technology.

The outside world will focus on Huawei, but the industry knows that it is impossible for Huawei to develop biological storage technology on its own.

It's not that they look down on Huawei. They admire Huawei's R&D capabilities. It's just that Huawei had no relevant technical reserves before, and it was completely unreasonable for it to come up with biological storage out of thin air.

Everyone's attention naturally focused on the Deep Blue Storage mentioned at Huawei's press conference.

The investigation did not reveal anything, except that Guan Yang of Yangtze Memory Technologies went there to serve as chairman.

The senior executives of these companies in the industry are also asking around to see if any team working on DNA macromolecule storage has been poached at domestic universities or research institutes.

I also haven't heard of any professors who had previously published papers on DNA storage leaving their jobs recently.

Just as Guan Yang had expected, after Hua Wei's press conference, there was no need for him to do door-to-door marketing as heads of various companies came to him one after another.

"Brother Guan, you are so mean. You have such advanced biological storage technology, but you didn't inform us first. We at Shuguang also have deep technical accumulation and rich experience in the field of storage servers."

As soon as the chairman of Inspur left, the chairman of Sugon came to the door. Li Jun did not beat around the bush and went straight to the point.

Sugon is also a state-owned enterprise, but it is not a state-owned enterprise directly managed by the central government. It is an enterprise incubated by the Ministry of Science and Technology and the Chinese Academy of Sciences. The current actual controller is the Institute of Computing Technology of the Chinese Academy of Sciences.

When Guan Yang was the vice president of Yangtze Memory Technologies, he was more than one level lower than Li Jun.

Guan Yang smiled and said, "The main reason is that our technology has just been developed and is not mature enough. There are still many areas that need to be improved, so we are not willing to cooperate with Sugon."

"When I was at Yangtze Memory Technologies, we were unable to collaborate with Sugon because the technology was not mature enough. This time when I came to DeepBlue Memory Technologies, the main reason is that the technology is still not mature enough."

Guan Yang hinted that Yangtze Memory Technologies Co., Ltd. previously hoped to penetrate into Sugon's supply chain system, but Sugon kept dragging its feet on the grounds that Yangtze Memory Technologies Co., Ltd.'s technology was not mature enough.

Sugon's storage server supplier has always been American-based Seagate, the world's largest manufacturer of hard disks and magnetic disks.

Seagate is definitely more mature in technology.

However, Yangtze Memory Technologies is a key national support project after all, and its goal at the time was not to directly replace Seagate, but to enter Sugon's supply chain system and only supply products if it met the conditions.

Even with such conditions, Shuguang did not agree.

Li Jun knew that Guan Yang was still upset about that incident, so he explained: "At that time, we wanted to choose Yangtze Memory, but we signed a three-year strategic cooperation agreement with Seagate in 18."

"Plus, Yangtze Memory's 64-layer flash memory technology was not yet mature at the time, and we didn't expect Yangtze Memory's technology to advance so quickly."

“We mastered 128-layer 3D NAND technology in just two years.”

Li Jun is just making excuses. The strategic cooperation agreement is not an exclusive agreement. Yangtze Memory's 64-layer flash memory technology can be first introduced into Sugon's low-end storage server models.

Guan Yang did not expose the other party. He was just making excuses to stall the other party. Since they had already changed companies, it was impossible for him to embarrass Li Jun because of some conflicts with Yangtze Memory Technologies.

Guan Yang only realized these days why he was appointed as the chairman of Deep Blue Storage. It was because he had a wide network of contacts and was specifically sent to reject these requests.

"Understood. Once the biological storage technology matures, we will authorize all Chinese companies."

"You don't have to worry."

"We are all state-owned enterprises. How could we not license our technology to Sugon?"

Thanks to Changqing 1040, Ishukō Fifth Spiral Arm Central Hub, Wang Weihuohua, Ao Shi Huansheng, and book friend 20201222095310546 for their rewards!


(End of this chapter)